bortezomib - Robuta Search

https://seer.cancer.gov/oncologytoolbox/canmed/ndconc/00409-1700/ 00409-1700 Bortezomib - CanMED: NDC CanMED: NDC. The Cancer Medications Enquiry Database (CanMED) is a two-part resource for cancer drug treatment related studies. bortezomib ndc https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a73d7ea7-d068-4d25-b368-fc3db1898be2 DailyMed - BORTEZOMIB injection, powder, lyophilized, for solution dailymed bortezomib injection powder lyophilized https://pubmed.ncbi.nlm.nih.gov/28352372/ Bortezomib-induced Severe Congestive Heart Failure The clinical manifestations of anti-cancer drug associated cardiac side effects are diverse and can range from acutely induced cardiac arrhythmias to severe... bortezomib induced severe heart failure https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1403424/full Frontiers | The SAR analysis of dietary polyphenols and their antagonistic effects on bortezomib at... Bortezomib (BTZ), a primary treatment for MM, but its effectiveness can be reduced by interactions with vicinal diol moieties (VDMs) in polyphenols. Despite ... https://profiles.wustl.edu/en/publications/bortezomib-is-a-rapid-mobilizer-of-hematopoietic-stem-cells-in-mi/ Bortezomib is a rapid mobilizer of hematopoietic stem cells in mice via modulation of the... https://pubmed.ncbi.nlm.nih.gov/16689991/ Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a... Based on literature, we hypothesize that baseline presence of sub clinical cardiomyopathy, characterized by a dysregulation of the ubiquitin-proteasome system,... cardiac failure https://www.nice.org.uk/guidance/TA129 Overview | Bortezomib monotherapy for relapsed multiple myeloma | Guidance | NICE Evidence-based recommendations on bortezomib monotherapy (Velcade) for treating relapsed multiple myeloma in adults multiple myeloma overview bortezomib relapsed guidance https://pubmed.ncbi.nlm.nih.gov/25787915/ Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib,... We aimed at demonstrating non-inferiority of bortezomib/cyclophosphamide/dexamethasone (VCD) compared to bortezomib/doxorubicin/dexamethasone (PAd) induction... phase iii trial bortezomib cyclophosphamide dexamethasone https://open.library.emory.edu/concern/publications/dfe6e8b8-b452-46bf-a9ef-6918f84d3885 Bortezomib for Patients with Advanced Stage Bronchioloalveolar Carcinoma (BAC): A California Cancer... Bortezomib for Patients with Advanced Stage Bronchioloalveolar Carcinoma (BAC): A California Cancer Consortium Phase II Study (NCI # 7003) for patients advanced stage https://adisinsight.springer.com/drugsafety/803552215?error=cookies_not_supported&code=9532fc21-77e2-4104-bd56-a239c2042a5e Bortezomib/cyclophosphamide/dexamethasone - AdisInsight A man in his 70s [exact age at onset not stated] exhibited lack of efficacy during treatment with bortezomib, cyclophosphamide and dexamethasone for cardiac bortezomib cyclophosphamide dexamethasone adisinsight https://adisinsight.springer.com/drugsafety/803040040?error=cookies_not_supported&code=1751b1ab-e2d8-4589-a931-0809eddd6d62 Bortezomib - AdisInsight A woman in her forties received bortezomib 1.3 mg/m2 [route and frequency of administration not stated] for antibody-mediated rejection of her kidney bortezomib adisinsight https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.861709/full Frontiers | Caspase-8: Friend or Foe in Bortezomib/Lenalidomide-Based Therapy for Myeloma Antiproliferation and proapoptosis are two major molecular mechanisms of action of drugs used for the treatment of multiple myeloma. Proteasome inhibitors. s... friend or foe https://adisinsight.springer.com/drugsafety/803004598?error=cookies_not_supported&code=23fc881d-b796-43a8-aea1-94f07717f56c Bortezomib - AdisInsight A 59-year-old man was diagnosed with multiple myeloma in May 2004, and started treatment with bortezomib [Velcade] in February 2006. Bortezomib 1.3 mg/m2 was bortezomib adisinsight https://adisinsight.springer.com/trials/700270404?error=cookies_not_supported&code=723d6a28-0949-4828-acc1-31d93e98c0a3 A Study to Evaluate the Diagnostic Yield of Biopsies and Compare the Effect of Bortezomib With... This study investigated the diagnostic yield of biopsies and compare the effect of bortezomib with other therapeutic strategies in ACAL patients. https://pubmed.ncbi.nlm.nih.gov/32296644/?dopt=Abstract Inhibition of microRNA-155 Reduces Neuropathic Pain During Chemotherapeutic Bortezomib via... As a chemotherapeutic agent, bortezomib (BTZ) is used for the treatment of multiple myeloma with adverse effect of painful peripheral neuropathy. Our current... neuropathic pain inhibition microrna reduces https://amsdottorato.unibo.it/id/eprint/2430/ Pralatrexate sinergizza in vitro ed in vivo con l'inibitore del Proteosoma Bortezomib in modelli... https://adisinsight.springer.com/drugsafety/803263717?error=cookies_not_supported&code=0f457363-7cc8-428a-93ea-ad556451043f Bortezomib/dexamethasone/thalidomide - AdisInsight A 37-year-old man developed cerebral venous thrombosis (CVT) during treatment with thalidomide, bortezomib, and dexamethasone [dosages and routes not bortezomib dexamethasone thalidomide adisinsight https://health.economictimes.indiatimes.com/news/pharma/zydus-receives-final-usfda-approval-for-bortezomib-injection/91313976 Zydus receives final USFDA approval for Bortezomib Injection, ETHealthworld Usfda: Bortezomib for injection is used to treat certain types of cancer, such as multiple myeloma and mantle cell lymphoma zydus receives final usfda approval https://www.scirp.org/journal/paperinformation?paperid=1125 Inhibition of proteasome by bortezomib increase chemosensitivity of bcr/abl positive human k562... Discover the synergistic apoptotic effects of imatinib and bortezomib in treating chronic myeloid leukaemia (CML). Explore the mechanisms behind increased... https://researchconnect.buffalo.edu/en/publications/impact-of-bortezomib-based-versus-lenalidomide-maintenance-therap/ Impact of bortezomib-based versus lenalidomide maintenance therapy on outcomes of patients with... https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-of-panobinostat-with-bortezomib-thalidomide-and-dexamethasone-for-myeloma-that-has-come-back-or-no-longer-responding-to-treatment-muk-six A trial of panobinostat with bortezomib, thalidomide and dexamethasone for myeloma that has come... This trial looked at a drug called panobinostat alongside bortezomib, thalidomide and dexamethasone for myeloma. https://health.economictimes.indiatimes.com/tag/bortezomib+cisplatin Bortezomib cisplatin - Latest bortezomib cisplatin , Information & Updates - Health -ET HealthWorld ETHealthworld.com brings latest bortezomib cisplatin news, views and updates from all top sources for the Indian Health industry. latest information bortezomib cisplatin updates health https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-study-see-bortezomib-and-an-epilepsy-drug-could-be-treatment-melanoma-or-bowel-cancer A study to see if bortezomib and an epilepsy drug could be a treatment for melanoma or bowel cancer This study was to find out how small doses of bortezomib (Velcade) and the epilepsy drug sodium valproate worked in people with melanoma or bowel cancer. https://open.library.emory.edu/concern/publications/1f8bc3a1-e7bd-4ec2-9ad0-fef1193f0ff3 A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of... A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the... https://pubmed.ncbi.nlm.nih.gov/34638498/ Reversal of Bortezomib-Induced Neurotoxicity by Suvecaltamide, a Selective T-Type Ca-Channel... This study evaluated suvecaltamide, a selective T-type calcium channel modulator, on chemotherapy-induced peripheral neurotoxicity (CIPN) and anti-cancer... https://adisinsight.springer.com/trials/700265909?error=cookies_not_supported&code=72f10ee9-c5bc-474a-af54-4d623b4056e4 A study to investigate if Bortezomib treatment response is related to NRAS/KRAS mutational status... This study investigated if Bortezomib treatment response is related to NRAS/KRAS mutational status in relapsed or refractory multiple myeloma patients. https://adisinsight.springer.com/drugsafety/803857789?error=cookies_not_supported&code=fb8420d5-b8d8-41f9-877e-682820332f9c Bortezomib/melphalan/prednisolone - AdisInsight A 70-year-old patient [sex not stated] exhibited lack of efficacy during treatment with bortezomib, melphalan and prednisolone for plasmoblast multiple bortezomib melphalan prednisolone adisinsight https://adisinsight.springer.com/drugsafety/803674158?error=cookies_not_supported&code=e1cd91a8-d6bd-489e-8a3f-14c811164206 Bortezomib - AdisInsight A 81-year-old man developed inflammatory myositis during treatment with bortezomib for multiple myeloma [route and dosage not stated].The man, who had a history bortezomib adisinsight https://pmc.ncbi.nlm.nih.gov/articles/PMC9814514/ Bortezomib abrogates temozolomide-induced autophagic flux through an ATG5 dependent pathway - PMC Introduction: Glioblastoma (GBM) is invariably resistant to temozolomide (TMZ) chemotherapy. Inhibiting the proteasomal pathway is an emerging strategy to... https://about.uq.edu.au/experts/project/38371 Frailty-stratified randomised controlled bayesian adaptive trial of bortezomib versus lenalidomide... frailty randomised controlled bayesian https://adisinsight.springer.com/drugsafety/803686223?error=cookies_not_supported&code=af11e92f-e5c5-483b-a62f-8dbc1bc7fc61 Bortezomib/methylprednisolone/plasma - AdisInsight A 74-year-old man developed axonal sensorimotor neuropathy during treatment with bortezomib for plasma cell leukaemia; he further experienced no therapeutic bortezomib methylprednisolone plasma adisinsight https://pubmed.ncbi.nlm.nih.gov/25745969/ [Bortezomib-associated acute congestive heart failure in a patient with multiple myeloma] We report an 81-year-old woman with multiple myeloma who developed acute cardiac injury after receiving bortezomib. The patient received weekly intravenous... congestive heart failure https://scholars.lib.ntu.edu.tw/entities/project/65217b22-3f07-4d68-aa30-e0780278fdbd Mechanisms of Neuropathic Pain in Bortezomib Neuropathy neuropathic pain mechanisms bortezomib neuropathy https://medlineplus.gov/druginfo/meds/a607007.html Bortezomib Injection: MedlinePlus Drug Information Bortezomib Injection: learn about side effects, dosage, special precautions, and more on MedlinePlus bortezomib injection medlineplus drug information https://researchconnect.buffalo.edu/en/publications/network-based-systems-analysis-explains-sequence-dependent-synerg/ Network-Based Systems Analysis Explains Sequence-Dependent Synergism of Bortezomib and Vorinostat... systems analysis https://adisinsight.springer.com/drugsafety/803926983?error=cookies_not_supported&code=4048d1f8-ab19-4612-bcae-da4bbafc73c9 Cyclophosphamide/Rituximab/Bortezomib - AdisInsight A 54-year-old man with phospholipase A2 receptor (PLA2R) antibody-positive primary membranous nephropathy experienced lack of efficacy during treatment with cyclophosphamide rituximab bortezomib adisinsight https://pubmed.ncbi.nlm.nih.gov/18949434/ Proteasome inhibition by bortezomib does not translate into efficacy on two malignant glioma... Bortezomib and other proteasome inhibitors have demonstrated an interesting antitumor activity against glioma cell lines. The present study aimed to evaluate... https://seer.cancer.gov/oncologytoolbox/canmed/hcpcs/956/ S0115 Bortezomib - CanMED: HCPCS CanMED: HCPCS. The Cancer Medications Enquiry Database (CanMED) is a two-part resource for cancer drug treatment related studies. bortezomib hcpcs https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0eb8daef-18da-43bb-b7c6-38c4c8b5dd80 DailyMed - BORTEZOMIB injection, powder, lyophilized, for solution dailymed bortezomib injection powder lyophilized https://adisinsight.springer.com/drugsafety/803924949?error=cookies_not_supported&code=b98b84a2-cecd-4732-be3c-fc3ecd4d4615 Bortezomib/Cyclophosphamide/Dexamethasone - AdisInsight A 65-year-old woman with multiple myeloma developed Listeria rhombencephalitis while receiving bortezomib, cyclophosphamide and dexamethasone, representing a bortezomib cyclophosphamide dexamethasone adisinsight https://seer.cancer.gov/oncologytoolbox/canmed/ndconc/70771-1708/ 70771-1708 BORTEZOMIB - CanMED: NDC CanMED: NDC. The Cancer Medications Enquiry Database (CanMED) is a two-part resource for cancer drug treatment related studies. bortezomib ndc https://pubmed.ncbi.nlm.nih.gov/35372089/ Efficacy of Intermittent, Oral Famciclovir Prophylaxis for Bortezomib-Induced Herpes Zoster in... Intermittent famciclovir prophylaxis is effective and safe in preventing herpes zoster development and can markedly reduce the duration of oral medicine... https://yoda.yale.edu/clinical-trial/nct02195479-a-phase-3-randomized-controlled-open-label-study-of-velcade-bortezomib-melphalan-prednisone-vmp-compared-to-daratumumab-in-combination-with-vmp-d-vmp-in-subjects-with-previousl/ NCT02195479 - A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib)... https://pubmed.ncbi.nlm.nih.gov/18949423/ Effects of combination treatment of bortezomib and dexamethasone in SCCHN cell lines depend on... Bortezomib has recently become the new treatment standard for relapsed or refractory multiple myeloma. We previously demonstrated that bortezomib also had a... https://pure.psu.edu/en/publications/bortezomib-lenalidomide-and-dexamethasone-in-transplant-eligible-/ Bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma... newly diagnosed bortezomib lenalidomide dexamethasone https://phs.weill.cornell.edu/research-collaboration/publications/phase-i-trial-palbociclib-plus-bortezomib-previously-treated A phase I trial of palbociclib plus bortezomib in previously treated mantle cell lymphoma. |... https://www.ncbi.nlm.nih.gov/Structure/pdb/6X27 6X27: Lon protease proteolytic domain complexed with bortezomib Lon protease homolog, mitochondrialN-[(1R)-1-(DIHYDROXYBORYL)-3-METHYLBUTYL]-N-(PYRAZIN-2-YLCARBONYL)-L-PHENYLALANINAMIDEPENTAETHYLENE GLYCOL lon protease domain bortezomib https://pubmed.ncbi.nlm.nih.gov/19190249/ Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based... The anticancer potency of green tea and its individual components is being intensely investigated, and some cancer patients already self-medicate with this... https://pubmed.ncbi.nlm.nih.gov/24880680/ Chitosan magnetic nanoparticles for pH responsive Bortezomib release in cancer therapy The use of nanotechnology in cancer treatment offers exciting opportunities, including the possibility of destroying tumors with minimal damage to healthy... magnetic nanoparticles chitosan ph https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-of-bortezomib-with-epirubicin-carboplatin-and-capecitabine-chemotherapy-for-cancer-where-the-food-pipe-meets-the-stomach A trial of bortezomib with epirubicin, carboplatin and capecitabine chemotherapy for cancer where... This trial looked at the drug bortezomib with chemotherapy for cancer that started where the food pipe (oesophagus) meets the stomach. https://pubmed.ncbi.nlm.nih.gov/27096326/ Bortezomib for the treatment of multiple myeloma This meta-analysis found that myeloma patients receiving bortezomib benefited in terms of OS, PFS and response rate compared to those who did not receive... for the bortezomib treatment multiple myeloma